CELL SURFACE MARKERS MARKET ANALYSIS

Global cell surface markers market is estimated to be valued at US$ 31.9 billion in 2023 and is expected to exhibit a CAGR of 8.6% during the forecast period (2023-2030).

Analysts’ views on global cell surface markers market:

Growing automation in laboratories, increasing adoption of in vitro diagnostics, new product launches, and strategies like mergers, acquisitions, and collaboration, and funding’s from government are expected to drive the global cell surface markers market growth over the forecast period. For instance, in September 2021, University of North Dakota (UND) Center of Biomedical Research Excellence (CoBRE) in Host-Pathogen interactions (HPI) was awarded with US$ 10.7 million renewal from National Institutes of Health (NIH) as funding for projects phase 2. Goal of this study is to have deeper understanding of host responses to viral, bacterial and parasitic infections leading to acute and chronic inflammatory diseases.

Figure 1. Global Cell Surface Markers Market Share (%), By Product Type, 2023

To learn more about this report, Request sample copy

Global Cell Surface Markers Market– Drivers

Increasing use of cell markers in diagnostics

Increasing use of cell markers in diagnostics of chronic diseases like cancer is expected to drive the global cell surface markers market growth over the forecast period. For instance, according to an article published by the Journal Molecular and Cellular Pathology published on January 7, 2021, High-content screening has been helpful in understanding the various downstream effects of various treatments on cancer cells, particularly on organelle targets, measuring the overall cellular response effectively for novel candidate compounds, and assessing signaling heterogeneity. The rising use in understanding cancer cell response to novel drugs is expected to drive market growth.

Increasing launches of new technologies and products for cell marking

Increasing launch of new products to make the cell marking process more efficient is expected to drive the global cell surface markers market growth. For instance, on August 12, 2020, IDEXX Laboratories, Inc., a U.S.-based healthcare innovation company, announced the launch of the ProCyte One Hematology Analyzer. The new analyzer’s advanced technology delivers breakthrough workflow simplicity and consistent, accurate results at the point of care.

Figure 2. Global Cell Surface Markers Market Share (%), By Region, 2023

To learn more about this report, Request sample copy

Global Cell Surface Markers Market- Regional Analysis

Among region, North America is estimated to hold a dominant position in the global cell surface markers market over the forecast period, owing to increasing launches of products. For instance, in March 2022, Beckman Coulter Inc., a U.S.-based global science and technology company, announced launch of CellMek SPS, a fully automated sample preparation system for clinical flow cytometry. It is a fully automated sample preparation system (SPS) offers on-demand processing for a multitude of sample types to help laboratories to expand capabilities.

Global Cell Surface Markers Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, the U.A.E., Egypt, and others faced problems regarding transportation of drugs from one place to another.

However, the COVID-19 pandemic had positive impact on the global cell surface markers market, due to increased demand for cell markers for COVID-19 testing. For instance, according to an article published by the Journal Biomedicines, on December 9, 2021, different immune responses indicate various COVID-19-specific immunological markers, which are used to improve flow cytometry assays for the diagnosis and tracking of COVID-19 progression and correlate with disease severity. According to the study, these markers could reveal the underlying causes of various reactions that might be brought on by a history of infections that are similar to the current one or by genetic, personal, and environmental variations.

Global Cell Surface Markers Market Segmentation:

Global cell surface markers market report is segmented into product type, application and region

Based on Product Type, the global cell surface markers market is segmented into flow cytometers, hematology analyzers, reagents and kits. Out of which, the flow cytometers segment is expected to dominate the market due to increasing launches of new products.

Based on Application, the global cell surface markers market is segmented into disease diagnosis and identification, research/drug discovery. Among these, disease diagnosis and identification segment is expected to dominate the market over the forecast period due to increasing use for treatment of diseases like cancers.

Based on Region, the global cell surface markers market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Among these, North America segment is expected to dominate the market over the forecast period due to increasing launch of products in this segment.

Among all segmentation, the product type segment has the highest potential due to increasing launches of products by the key market players. For instance, on June 7, 2021, Thermo Fisher Scientific, Inc., a U.S.-based Laboratory equipment supplier, announced the launch of the Invitrogen Attune CytPix Flow Cytometer, an imaging-enhanced flow cytometer that combines acoustic focusing flow cytometry technology with a high-speed camera. The Attune CytPix allows users to collect high-performance fluorescent flow cytometry data from cells while simultaneously capturing high resolution bright field images, allowing users to match images with their flow cytometry data to better understand the morphology and quality of the cells. The Invitrogen Attune CytPix Flow Cytometer is a user-friendly, modular benchtop instrument that enables researchers working in QA/QC or cell therapy applications.

Global Cell Surface Markers Market Cross Sectional Analysis:

Introduction of newer products and technologies in cell culture by key market players in Europe region is expected to drive growth of product type segment in the region. For instance, on April 12, 2022, Sysmex Europe SE, Europe based company designing and producing diagnostic solutions for medical laboratories, announced that it has launched its new three-part differential automated hematology analyzer XQ-320. The XQ-320 is a robust device, with low demands for sample volume, bench space, and maintenance. It is easy to operate, include fast user log on via barcode and quick start-up, and presents the results at a glance in less than a minute, offers range of functions related to quality control and patient data safety.

Global Cell Surface Markers Market: Key Developments

On March 14, 2022, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., a China-based global leading medical solution provider, launched the new BC-700 Series, a revolutionary hematology analyzer series that incorporates both complete blood count (CBC) and erythrocyte sedimentation rate (ESR) tests. This series, including two open vial models BC-700/BC-720 and two autoloader models BC-760/BC-780, is designed to empower medium-volume laboratories with advanced diagnostics technologies that are applied in the premium products. Such launch of more efficient products can drive market growth.

On January 2, 2023, Diatron, a Europe-based Laboratory equipment supplier, announced the launch of Aquarius 3, its latest in vitro diagnostic (IVD) hematology analyzer for Complete Blood Count testing. Aquarius 3 will be the first in a new family of hematology analyzers from Diatron. Evolving from the Abacus 380, Diatron’s flagship analyzer, the Aquarius 3 incorporates similar robust counting technology but is equipped with new features to improve operability and connectivity, allowing it to adapt to diverse environments for the benefit of both customers and users alike.

On May 4, 2021, Beckman Coulter Inc., U.S. based global science and technology  company, launched next-generation CytoFLEX SRT benchtop cell sorter. It can sort, and feature expanded laser and color options for use in labs of all sizes. The CytoFLEX SRT is a benchtop cell sorter and offers up to four lasers and 17 detection channels to help accelerate answers in genomics and immune-phenotyping workflows.

On May 18, 2023, Sysmex Corporation, a Japan-based health care company, announced launch of its Clinical Flow Cytometry System, which combines the Flow Cytometer XF-1600, Sample Preparation System PS-10, antibody reagents and other related products. The system makes it possible for laboratories to automate the entire testing process, from sample preparation to the reporting of measurement results in clinical Ferric carboxymaltose (FCM) testing. This achieves higher efficiency and standardization of testing and reduces the burden placed on clinical technologists, allowing them to focus on the more technically demanding analysis of testing results.

Global Cell Surface Markers Market: Key Trends

Introduction of newer instruments for efficient cell marker techniques

Introduction of newer and more efficient instruments to boost up cell marker techniques can drive growth of market. On December 21, 2020, Nihon Kohden Corporation, a Japan-based medical device company, launched MEK-1305 Celltac α+, an Automated Hematology and erythrocyte sedimentation rate (ESR) Analyzer. MEK-1305 is the first hematology analyzer which can measure complete blood count (CBC) including white blood cell 3-part differential and erythrocyte sedimentation rate (ESR) simultaneously. The company developed MEK-1305 based on the concept of providing rapid and accurate test results, which are important for understanding the clinical condition of patients.

Acquisition strategy by key market players

Strategies such as acquisition by key market players can drive growth of market. For instance, on February 19, 2020, Promedior Inc., a U.S.-based clinical-stage biopharmaceutical company, was acquired by F. Hoffmann-La Roche AG., a Switzerland-based healthcare company. With this acquisition, Roche gets full rights of Promedior’s entire portfolio of molecules for serious fibrotic diseases, most notably PRM-151. Under the terms of the merger agreement, Roche made an upfront cash payment of US$ 390 million, with additional contingent payments of up to US$ 1 billion to be made on achievement of certain predetermined development, regulatory and commercial milestones.

Global Cell Surface Markers Market: Restraints

High Cost of instruments used in cell marking

The high cost of instruments used in cell marking is expected to hamper the global cell surface markers market growth. For instance, according to an article published by the Journal Advanced Intelligent Systems, on July 26, 2021, major hurdle for mass deployment of these machine learning algorithms to commercial imaging flow cytometry for real-time object identification and classification because of the high cost and high power consumption. The average price of a flow cytometer is US$ 125,000. As of July 2021, the average cost of a flow cytometer varies between US$ 100,000 to US$ 500,000 for a single unit.

To counterbalance this restraint, cost efficient instruments should be introduced. 

Product recalls from market

The recalls of products due to non-adherence to government protocols or lack of activity is expected to hamper the global cell surface markers market growth. For instance, on December 30, 2021, U.S. Food and Drug Administration (FDA) issued Class I recall of three hematology analyzers by Beckman Coulter Inc., a U.S.-based global science and technology company,  DxH 800, DxH 600, and DxH 900 after reports of inaccurate platelet counts. U.S. FDA stated that an inaccurate result may lead a provider to conclude a patient is suitable for surgery, when patient may not be, to withhold platelet transfusion in patients who may need it, or to delay or miss the diagnosis of serious blood disorders.

To counterbalance this restrain, stringent research activities should be done before getting approval for product.

Global Cell Surface Markers Market- Key Players

Major players operating in the global cell surface markers market include Abbott Laboratories, Inc., Beckman Coulter, Inc., BD Biosciences, Bio-Rad Laboratories, Inc., Grifols SA, Immucor, Inc., Janssen Diagnostics, Inc., Nihon Kohden Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthcare, Sysmex Corporation, and Thermo Fisher Scientific, Inc.

*Definition: Cell surface markers are distinct molecules that are present on cell surfaces. Cell surface markers are used to identify and classify different cells. These markers play a vital role in immunology. Hematology analysis involves diagnosis and identification of such markers in order to make a diagnosis. Instruments such as flow cytometers, and hematology analyzers are used for this purpose.